Abstract Title:

[Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].

Abstract Source:

Vopr Onkol. 2003;49(2):198-204. PMID: 12785205

Abstract Author(s):

V F Semiglazov, S Ia Maksimov, E A Bulgatova, I E Meshkova, O F Chepik, L M Berstein

Article Affiliation:

N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.

Abstract:

The antiestrogen drug tamoxifen, which is widely used in adjuvant hormone therapy of breast cancer, presents certain risk of causing hyperplasia and endometrial carcinoma. Our clinical data on 1,969 breast cancer patients (stage I-III) (tamoxifen--947; control--1,022) showed a double rise in endometrial carcinoma risk in cases receiving hormone therapy. Endometrial carcinoma incidence in tamoxifen-treated patients was 3% while in the untreated ones--1.6% (p<0.05). According to the endometrial tissue study in 439 breast cancer patients, proliferative effect of tamoxifen in the form of endometrial hyperplasia was 5--6 times in tamoxifen users. Meanwhile, endometrial carcinoma and hyperplasia risk increased during a much longer exposure to tamoxifen and in combination with such factors as obesity, diabetes mellitus, uterine myoma and estrogen-type colpocytological response. Hence, breast cancer patients need to undergo dynamic follow-up of the endometrium including ultrasonic examination of the small-pelvis organs and cytological study of ecto- and endocervical smears and endometrial aspirates.

Study Type : Human Study
Additional Links
Problem Substances : Tamoxifen : CK(401) : AC(68)
Adverse Pharmacological Actions : Carcinogenic : CK(1048) : AC(158)

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.